At GSK, we're driven by our deep understanding of the root causes of disease. We focus our R&D in areas like cancer, HIV, and respiratory diseases where we can make the most meaningful difference for people. By uniting science, technology, and talent, we prevent and treat disease with specialty medicines, vaccines, and general medicines, partnering with the world’s leading minds to drive innovation.
Dr. Chung explores the critical necessity of multidisciplinary team (MDT) integration in the era of immunotherapy. The session focuses on the complex communication pathways required between surgical and oncology teams to optimize patient selection and treatment sequencing. Dr. Chung provides a framework for implementing immunotherapy pathways, managing multidisciplinary decision-making processes, and navigating the logistical challenges of treating complex colorectal cancer patients in a synchronized, collaborative environment.
Published
Aug 2026
A surgical deep-dive into the technical nuances of resecting MSI-H colorectal cancers. Dr. Atallah outlines the essential surgical strategies for patients undergoing neoadjuvant immunotherapy, emphasizing the timing of resection and the management of tissue response. The lecture reviews surgical decision-making, procedural safety in the post-immunotherapy setting, and the utilization of minimally invasive approaches to enhance recovery and oncological precision.
Published
Aug 2026
Dr. André presents a critical analysis of real-world evidence for MSI-H/dMMR colon cancer, focusing on the paradigm shift driven by immune checkpoint inhibitors. The presentation bridges clinical oncology and surgical integration, discussing long-term survival benefits observed in clinical practice. The session provides an in-depth review of key landmark studies and explores how these evidence-based results are effectively translated into current standard-of-care pathways for colorectal cancer patients.
Published
Aug 2026
Dr. Christenson examines the current landscape of immunotherapy in mismatch-repair proficient (pMMR) colorectal cancer, a cohort historically resistant to immune checkpoint inhibitors. The session explores the molecular rationale behind current resistance and reviews emerging strategies to sensitize pMMR tumors to immunotherapy. Through clinical data and research insights, the lecture highlights potential combination therapies and innovative approaches to improve patient outcomes in this challenging patient population.
Published
Aug 2026
Share it with your network and help spread clinical knowledge.
